跳至主要内容
临床试验/NCT01694680
NCT01694680已完成不适用

Intervention Study to Assess the Effect of Daily Consumption of a Lutein-enriched-egg Beverage on Maintenance of Visual Function in Subjects With Early Signs of Age-related Macular Degeneration

Newtricious R&D BV4 个研究点 分布在 4 个国家目标入组 120 人开始时间: 2012年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
120
试验地点
4
主要终点
Visual function

研究概览

简要总结

The purpose of the I-TEAM project is to assess whether there is a change in visual function and status of the retina after a year of intervention in subjects with early signs of Age-related Macular Degeneration.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Early AMD (AREDS category 2)
  • •many small drusen, or
  • •a few intermediate-sized (63-124 micrometres in diameter) drusen, or
  • •macular pigmentary changes
  • •Intermediate AMD (AREDS category 3)
  • •extensive intermediate sized (63-124 micrometres in diameter) drusen, or
  • •at least one large (>125 micrometers in diameter) drusen or
  • •geographic atrophy not involving the foveal centre
  • •men and women age ≥50 years
  • •BMI 18-35 kg/m2
  • •Vision ≥ 20/40 for Snellen visual acuity
  • •lutein intake of < 2 mg/day (including supplements)
  • •DHA intake of < 150 mg/day (including supplements)
  • •must be able to give written informed consent
  • •have normal hematologic parameters
  • •normal values of plasma albumin
  • •normal values for liver and kidney function
  • •no use of carotenoid, fish oil, or n3 fatty acid supplements (within 1 month of study start)

排除标准

  • •ocular media opacity (severe cataract)
  • •history of active small bowel disease or resection
  • •atrophic gastritis
  • •history of hyperlipidemia or screening values as follows (LDL > 5.33mmol/L or 205mg/dL; triglycerides > 4.52mmol/L or >400 mg/dL)
  • •hypertension (>150/90 mm Hg)
  • •diabetes mellitus (if also accompanied by signs of diabetic retinopathy)
  • •alcohol intake of >2 drinks/day or 14 drinks/week
  • •pancreatic disease
  • •dementia or Alzheimer's disease
  • •anemia, and bleeding disorders
  • •known allergy to egg or egg products
  • •known allergy to milk or milk products
  • •known allergy to cocoa or chocolate products
  • •known allergy to fish or fish oils
  • •lactose intolerance
  • •pregnancy or lactation
  • •diseases that interfere with fat absorption, e.g. colitis, celiac disease, Crohn's disease, cystic fibrosis (as determined by screening interview)
  • •medication or supplements that contain a significant level of carotenoids, including an amount of lutein of more than 0.25 mg per day within 1 month of the study start
  • •medications that interfere with fat absorption, e.g. bile sequestrants (as determined by screening interview)
  • •use of antipsychotic, anti manic, or dementia medications
  • •smoking or use of nicotine patches or gum (within the past 6 months)
  • •subjects having extremely high dietary intakes of carotenoids
  • •stroke, head injury with loss of consciousness or seizures
  • •for US and UK center: Non English speaking

研究组 & 干预措施

Lutein-enriched-egg beverage

Active Comparator

Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage

干预措施: Lutein-enriched-egg beverage (NWT-02) (Dietary Supplement)

Placebo

Placebo Comparator

Powder in sachet to prepare beverage

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Visual function

时间窗: 12 months

次要结局

  • Carotenoid levels(12 months)

研究者

发起方
Newtricious R&D BV
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验